



PRODUCT: **Adhansia XR®**

COMPANY: Adlon Therapeutics L.P.,  
a subsidiary of Purdue Pharma L.P.

THERAPEUTIC AREA & INDICATION:

Central nervous system stimulant to treat attention  
deficit hyperactivity disorder (ADHD)  
in people age six and older

ABOUT THE PRODUCT

Adhansia XR contains methylphenidate (MPH) and is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older. Adhansia XR capsules contain identical beads which are formulated using the proprietary smart design MLR™ (Multi-Layer Release) technology. Each bead has an immediate-release component (containing 20% of the dose) and a controlled-release component (containing 80% of the dose). Adhansia XR is the first and only single daily dose MPH medication that demonstrates efficacy starting at 1 hour and continuing throughout the day up to, and including, 16 hours post-dose in adults.